# Endocyte and ITM sign long-term supply agreement for Lutetium-177

Endocyte and ITM subsidiary ITG signed a long-term global supply agreement for no-carrier-added Lutetium-177 (EndolucinBeta) to support clinical and commercial supply of 177Lu-PSMA-617 through 2035. Endocyte will pay €5 million upfront to support ITM's expansion of manufacturing capacity.

- Type: Contract
- Announced: 2018-07-09
- Value: $5.80M (5.00M EUR)
- Status: announced
- Products: no-carrier-added Lutetium-177, 177Lu-PSMA-617
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [Endocyte](https://endata.com/companies/32999.md) (customer)
- [ITM Isotopen Technologien München](https://endata.com/companies/33000.md) (supplier)
- [Isotope Technologies Garching](https://endata.com/companies/33001.md) (supplier)

## Sources

- [itm-radiopharma.com](https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/endocyte-and-itm-announce-long-term-supply-agreement-for-no-carrier-added-lutetium-177-66/), 2018-07-09: "We are pleased to secure this long-term strategic partnership to ensure a reliable supply of no-carrier-added Lutetium-177 through commercialization."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.